| Cancer burden in the HIV-infected population in the United States MS Shiels, RM Pfeiffer, MH Gail, HI Hall, J Li, AK Chaturvedi, K Bhatia, ... Journal of the National Cancer Institute 103 (9), 753-762, 2011 | 862 | 2011 |
| International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease DC Fajgenbaum, TS Uldrick, A Bagg, D Frank, D Wu, G Srkalovic, ... Blood, The Journal of the American Society of Hematology 129 (12), 1646-1657, 2017 | 504 | 2017 |
| HIV-associated cancers and related diseases R Yarchoan, TS Uldrick New England Journal of Medicine 378 (11), 1029-1041, 2018 | 470 | 2018 |
| Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement ES Kim, SS Bruinooge, S Roberts, G Ison, NU Lin, L Gore, TS Uldrick, ... Journal of Clinical Oncology 35 (33), 3737, 2017 | 400 | 2017 |
| Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo FR Simonetti, MD Sobolewski, E Fyne, W Shao, J Spindler, J Hattori, ... Proceedings of the National Academy of Sciences 113 (7), 1883-1888, 2016 | 379 | 2016 |
| International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease F Van Rhee, P Voorhees, A Dispenzieri, A Fosså, G Srkalovic, M Ide, ... Blood, The Journal of the American Society of Hematology 132 (20), 2115-2124, 2018 | 324 | 2018 |
| Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV working group TS Uldrick, G Ison, MA Rudek, A Noy, K Schwartz, S Bruinooge, ... Journal of clinical oncology: official journal of the American Society of …, 2017 | 315 | 2017 |
| An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease TS Uldrick, V Wang, D O'Mahony, K Aleman, KM Wyvill, V Marshall, ... Clinical Infectious Diseases 51 (3), 350-358, 2010 | 301 | 2010 |
| Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma TS Uldrick, D Whitby Cancer letters 305 (2), 150-162, 2011 | 231 | 2011 |
| Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome MN Polizzotto, TS Uldrick, D Hu, R Yarchoan Frontiers in microbiology 3, 73, 2012 | 193 | 2012 |
| Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer—a phase 1 study TS Uldrick, PH Gonçalves, M Abdul-Hay, AJ Claeys, B Emu, MS Ernstoff, ... JAMA oncology 5 (9), 1332-1339, 2019 | 191 | 2019 |
| Clinical and pathological characteristics of HIV-and HHV-8–negative Castleman disease LI Yu, M Tu, J Cortes, ZY Xu-Monette, RN Miranda, J Zhang, RZ Orlowski, ... Blood, The Journal of the American Society of Hematology 129 (12), 1658-1668, 2017 | 172 | 2017 |
| Kaposi sarcoma–associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment M Bhutani, MN Polizzotto, TS Uldrick, R Yarchoan Seminars in oncology 42 (2), 223-246, 2015 | 172 | 2015 |
| Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV inflammatory … MN Polizzotto, TS Uldrick, KM Wyvill, K Aleman, V Marshall, V Wang, ... Clinical Infectious Diseases 62 (6), 730-738, 2016 | 170 | 2016 |
| Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease MN Polizzotto, TS Uldrick, V Wang, K Aleman, KM Wyvill, V Marshall, ... Blood, The Journal of the American Society of Hematology 122 (26), 4189-4198, 2013 | 168 | 2013 |
| Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK … JR Abend, T Uldrick, JM Ziegelbauer Journal of virology 84 (23), 12139-12151, 2010 | 163 | 2010 |
| High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy TS Uldrick, MN Polizzotto, K Aleman, D O'Mahony, KM Wyvill, V Wang, ... Blood, The Journal of the American Society of Hematology 117 (26), 6977-6986, 2011 | 158 | 2011 |
| Kaposi sarcoma herpesvirus-associated cancers and related diseases PH Goncalves, J Ziegelbauer, TS Uldrick, R Yarchoan Current Opinion in HIV and AIDS 12 (1), 47-56, 2017 | 154 | 2017 |
| A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated … A Mosam, F Shaik, TS Uldrick, T Esterhuizen, GH Friedland, DT Scadden, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 60 (2), 150-157, 2012 | 148 | 2012 |
| Discovery of Kaposi’s sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA T Tagawa, S Gao, VN Koparde, M Gonzalez, JL Spouge, AP Serquiña, ... Proceedings of the National Academy of Sciences 115 (50), 12805-12810, 2018 | 144 | 2018 |
Mark PolizzottoClinical Hub for Interventional Research (CHOIR), The Australian National UniversityVerified email at anu.edu.au
